Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2014-01-21
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bortezomib and lenalidomide work in treating patients
with mantle cell lymphoma that has come back after a period of improvement (refractory) or is
not responding to treatment (refractory). Bortezomib may also stop the growth of cancer cells
by blocking some proteins needed for cell growth. Lenalidomide may stimulate the immune
system to kill cancer cells and may also block the growth of new blood vessels necessary for
cell growth. Giving bortezomib with lenalidomide may be an effective treatment for relapsed
or refractory mantle cell lymphoma.